Natural Protein Points to New Inflammation Treatment Findings may offer insight to effective treatments for inflammatory diseases, such as rheumatoid arthritis, psoriasis, and multiple sclerosis.Tricked-Out Immune Cells Could Attack Cancer New cell-engineering technique may lead to precision immunotherapies.Therapy Halts Progression of Lou Gehrig’s Disease Researchers at Oregon State University announced today that they have essentially stopped the progression of amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, for nearly two years in one type of mouse model used to study the disease – allowing the mice to approach their normal lifespan.Crouching Protein, Hidden Enzyme A new study led by scientists at The Scripps Research Institute (TSRI) and the University of California (UC), Berkeley shows how a crucial molecular enzyme starts in a tucked-in somersault position and flips out when it encounters the right target.Utilizing Antibodies from Ebola Survivors A collaborative team from The University of Texas Medical Branch at Galveston, Vanderbilt University, The Scripps Research Institute and Integral Molecular Inc. have learned that antibodies in the blood of people who have survived a strain of the Ebola virus can kill various types of Ebola.Engineering Foe into Friend Bose Grant awardee Jacquin Niles aims to repurpose the malaria parasite for drug delivery.Important Regulator of Immune System Decoded Plasma cells play a key role in our immune system. Now scientists at the Research Institute of Molecular Pathology (IMP) in Vienna, Austria, and at the Walter and Eliza Hall Institute (WEHI) in Melbourne, Australia, succeeded in characterizing a central regulator of plasma cell function.Bacterial Superglue for Faster Vaccine Development An interdisciplinary team of Oxford University researchers has devised a new technique to speed up the development of novel vaccines.Enumeral, MD Anderson Enter Into Collaboration Strategic collaboration aims to discover and develop potentially novel antibodies against specified targets for immunotherapy.Joint venture for GlycoMar Limited and MicroA AS Scottish biotechnology company GlycoMar and Norwegian technology company MicroA are pleased to announce their joint venture business Prasinotech Ltd. The new company is registered in Scotland.
02 Feb 2014 - 04 Feb 2014 Texas A&M university, TX, USA Fermentation and Separation for the Food & Drug Industries Short Course
17 Feb 2014 - 20 Feb 2014 Frankfurt, Germany World ADC Frankfurt
17 Feb 2014 - 17 Feb 2014 Milton Keynes, UK 1-day Basics of Deconvolution training course (AMDIS)
18 Feb 2014 - 19 Feb 2014 Barcelona, Spain ADME & Predictive Toxicology
24 Feb 2014 - 25 Feb 2014 Mumbai, India Generics and Biologics 2014
25 Feb 2014 - 27 Feb 2014 Munich, Germany Cell Culture World Congress 2014
26 Feb 2014 - 27 Feb 2014 Taipei, Taiwan Biologics World Taiwan 2014